Report Sections

See All Reports

  • HP:0002315: Headache
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002315: Headache

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (9)


    Name (Synonyms) Correlation
    drug2006 Mindfulness Wiki 0.71
    drug3232 Symptomatic drugs Wiki 0.50
    drug2014 Mindfulness program Wiki 0.50
    Name (Synonyms) Correlation
    drug3103 Sphenopalatine Ganglion Block with Placebo (Isotone NaCl) Wiki 0.50
    drug2 "Sham"-block with Placebo (Isotone NaCl) Wiki 0.50
    drug3102 Sphenopalatine Ganglion Block with Local Anesthetic Wiki 0.50
    drug4066 vaccine Wiki 0.50
    drug510 Bridge therapy Wiki 0.50
    drug3897 no intervention Wiki 0.16

    Correlated MeSH Terms (6)


    Name (Synonyms) Correlation
    D006261 Headache NIH 1.00
    D008881 Migraine Disorders NIH 0.58
    D051271 Headache Disorders, Secondary NIH 0.50
    Name (Synonyms) Correlation
    D013581 Synovial Cyst NIH 0.50
    D045888 Ganglion Cysts NIH 0.29
    D004630 Emergencies NIH 0.08

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0002076 Migraine HPO 0.58

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency

    Chronic Migraine is a disabling condition that affects the 2% of migraine population. It is often associated with medication overuse that makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse but it is also confirmed that patients have to be carefully followed in the last period after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. It has been also reported how the clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. Generally patients after withdrawal follow a specific prophylaxis for migraine, but also come weekly to the hospital for practicing mindfulness for 6 sessionsAs the emergency situation due to the Corona-virus pandemic phenomenon in Italy, patients will miss the possibility to come for the regular practice to the hospital: for this reason the investigator propose a small pilot study to enforce the use of technology for our patients so that they can continue to be followed in their therapeutic process. This preliminary study will be conducted on 25 patients that have been submitted to a withdrawal according to the standard procedure at our hospital and they will practice mindfulness daily by a standard session of 12 minutes on their smartphone recorded by the expert who generally manage their sessions at the hospital and also a weekly video-call to evaluate the clinical condition and to encourage to use strategies for pain management. This modality will allow the patients to continue their therapeutic process and to be followed regularly during the one year after withdrawal

    NCT04389372
    Conditions
    1. Migraine Headache
    Interventions
    1. Behavioral: Mindfulness
    MeSH:Migraine Disorders Headache
    HPO:Headache Migraine

    Primary Outcomes

    Description: Changes in migraine /days per month and medication intake/month (decrease of at least 50% in at least 50% of CM-MO patients)

    Measure: Efficacy of Mindfullness by Smartphone

    Time: at 6 months and 12 months follow-up compared with baseline (Headache Daily Diary)

    Secondary Outcomes

    Description: Changes in disability, impact Migraine Disability Assessment Score (MIDAS questionnaire) minimum score 0-maximum score 270 HIGHER SCORES worse outcome (they indicate more disability)

    Measure: Change of Disability Score

    Time: 6months - 12months

    Description: Changes in Headache Impact Test (HIT-6) minimum score 36- maximum score 78 HIGHER SCORES worse outcome (they indicate more impact)

    Measure: Change in Quality of life

    Time: 6months - 12 months
    2 Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up

    Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse, but it is also confirmed that patients have to be carefully followed after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. Clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. As the emergency situation due to the Corona-virus pandemic phenomenon in Italy, the regular clinical practice adopted for patients with CM-MO has changed in the last weeks: patients cannot come to the hospital for the withdrawal iv therapy and for regular follow up as the reduced mobility due to the emergency in particular in the Lombardia region, but all over Italy. So the investigators propose a pilot study to enforce the application of a Home-program for the withdrawal procedure for patients and the use of technology like smartphone and video calls so that patients can continue to be followed in their therapeutic process by using behavioral support and mindfulness practice. Patients will perform the withdrawal program at home, by oral administration of therapies, with specific instructions and education. Also the information for behavioral approach and mindfulness practice will be given, to use every day at home. Daily standardized mindfulness sessions of 12 minutes on their smartphone will be combined with weekly video-call to evaluate the clinical condition and to encourage the use strategies for pain management. Face-to-face visits at the follow up every three months will be scheduled. This modality will allow the patients to continue their therapeutic process and to be regularly followed during the one year after withdrawal.

    NCT04410536
    Conditions
    1. Migraine, Hemicrania
    Interventions
    1. Drug: Symptomatic drugs
    2. Drug: Bridge therapy
    3. Behavioral: Mindfulness program
    MeSH:Headache Disorders, Secondary Migraine Disorders Emergencies Headache
    HPO:Headache Migraine

    Primary Outcomes

    Description: Drop-out rates after withdrawal treatment

    Measure: Drop out rates

    Time: at 12 months

    Secondary Outcomes

    Description: Percentages of patients with absence of Medication Overuse Headache

    Measure: Absence of Medication Overuse Headache (MOH)

    Time: at 12 months from withdrawal program (assessed by Daily Diary Card)
    3 Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Chronic Migraine and High Frequency Migraine Without Aura After the Covid-19 Emergency

    Chronic Migraine and Migraine without aura at high frequency are disabling conditions also in adolescence age (2% of adolescents report chronic migraine) Common pharmacological treatments are often inadequate. It has been reported that clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patients to become more conscious about their symptoms and able to manage pain without medication. Generally, according to standard clinical practice, young patients (12-17 yrs old) treated by mindfulness practice come to the hospital to practice mindfulness in small groups of patients for 6 weekly 45 minutes sessions. As the emergency situation due to the Corona-virus pandemic phenomenon in Italy, patients missed the possibility to come for the regular practice to the hospital: for this reason the investigators propose a small pilot study to enforce the use of technology for patients so that they can continue to be followed during their therapeutic process. This preliminary study will be conducted on 25 patients They will be trained to practice mindfulness daily by a standard session of 12 minutes on their smartphone recorded by the expert who generally manage their sessions at the hospital. Also a weekly video-session will be performed to evaluate the clinical condition, to practice guided mindfulness sessions and to encourage to use strategies for pain management . This modality will allow patients to continue their therapeutic process and to be followed regularly during the one year after treatment. Follow up sessions are planned every three months: these meetings at the hospital will be face-to-face with every patient to check the clinical condition by the patient's diary. Last follow up one year after treatment.

    NCT04604977
    Conditions
    1. Headaches Chronic
    Interventions
    1. Behavioral: Mindfulness
    MeSH:Headache
    HPO:Headache

    Primary Outcomes

    Description: reduction of at least 50 % of headache days during the treatment period

    Measure: reduction of headache days

    Time: at 6 months and 12 months follow-up compared with baseline (Headache Daily Diary)

    Secondary Outcomes

    Description: reduction of at least 50 % of headache days until the last follow up (assessed by Daily Diary Card)

    Measure: reduction of headache days until last follow up

    Time: at 12 months from withdrawal program (assessed by Daily Diary Card)

    Description: decrease in disability score (Ped MIDAS) - (score of PedMIDAS: 0-10 little disability; 11-30 mild disability; 31-50 moderate disability; more than 50 severe disability)

    Measure: disability score

    Time: 6 months - 12 months

    Description: decrease in catastrophising attitude (PCS) - Score more than 30 : clinically relevant level of catastrophising

    Measure: catastrophising attitude

    Time: 6 months - 12 months

    Description: decrease in depression symptoms (Kovacs) - score =15 mild depression; 15-20 moderate depression; more than 25 severe depression);

    Measure: depression symptoms

    Time: 6 months - 12 months

    Description: decrease in trait-state anxiety symptoms (STAI X1-X2) - score more than 40 anxiety symptoms abnormal

    Measure: trait-state anxiety symptoms (STAI X1-X2)

    Time: 6 months - 12 months
    4 The Effect of Ganglion Sphenopalatine Block (SPG-block) Versus Placebo on Persistent Headache Following COVID-19 Infection: a Randomised, Blinded, Clinical Trial

    The purpose of this study is to evaluate the effect of the ganglion sphenopalatine block (SPG block) on persistent headache following acute COVID-19 infection.

    NCT04636034
    Conditions
    1. Headache
    2. Covid19
    3. Sphenopalatine Ganglion Block
    4. Persistent Headache Following COVID-19
    Interventions
    1. Procedure: Sphenopalatine Ganglion Block with Local Anesthetic
    2. Procedure: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)
    3. Procedure: "Sham"-block with Placebo (Isotone NaCl)
    MeSH:Ganglion Cysts Synovial Cyst Headache
    HPO:Headache

    Primary Outcomes

    Description: Pain intensity will be measured as worst experienced pain after the patient has been standing for 30 seconds or the worst experienced pain while attempting to stand if the rating has to be interrupted.

    Measure: Hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, VAS) of the postdural headache in standing position in the group Ropivacine-Lidocaine and "sham".

    Time: 30 minutes after block

    Secondary Outcomes

    Description: Pain intensity measured as worst experienced pain after the patient has been standing for 30 seconds or the worst experienced pain while attempting to stand if the rating has to be interrupted.

    Measure: Number of patients with pain rating below 30mm in standing position (0-100mm on a visual analogue scale, VAS)

    Time: 30 minutes and 1 week after block

    Description: The worst experienced pain reported during the week following the block as registered by the patient.

    Measure: Worst experienced pain in standing position (0-10 on a numercial rating scale, NRS)

    Time: During study period until completion of 1 week follow up

    Description: The average pain intensity reported during the week following the block as registered by the patient.

    Measure: Average pain intensity (0-10 on a numercial rating scale, NRS)

    Time: During study period until completion of 1 week follow up

    Description: If the patient at the 1 week follow up still needs further treatment a "rescue SPG-block" defined as a new SPG-block with "open label" analgetics will be offered.

    Measure: Number of patients needing "rescue GSP-block"

    Time: At 1 week follow up

    Description: Pain intensity will be measured as worst experienced pain after the patient has been standing for 30 seconds or the worst experienced pain while attempting to stand if the rating has to be interrupted.

    Measure: Hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, VAS) of the postdural headache in standing position in all 3 groups.

    Time: 30 minutes after block

    Other Outcomes

    Description: The use of analgesics during the week following the block as registered by the patient and the patient file.

    Measure: Analgesics used daily in the week following the SPG-block

    Time: During study period until completion of 1 week follow up

    HPO Nodes


    HP:0002315: Headache
    Genes 344
    NLRP3 ACSF3 SH2B1 CFI NAGS ND6 DKK1 TRNL1 RPS20 COL1A1 TRNK SOST TRNC SMO BRAF CDKN2C TWNK VHL CYP11B2 NHLRC1 CNNM2 APC RET APP KCNJ5 PEX11B CDH23 SH2B3 TRNS2 SPECC1L CTNNB1 CNTN2 SLC1A3 TNFRSF1A SLC2A1 MYORG TTR SPOP ND1 MPL KCNK18 CPT2 CDH23 PDGFB POLG IL12B HLA-DPA1 SLC2A1 EPCAM MSX2 IL10 ATP6 RRM2B SDHB DNAI1 TGFBR2 KCNA1 SDHD GBA CORIN ENG HTR1A MAOA RNASEH1 RNASEH2C NF1 LRP5 GCDH ADA2 RRM2B KRIT1 NOTCH3 TREX1 TWNK CCM2 SMARCB1 FLT1 SMARCE1 BAP1 MEN1 COX1 UNC93B1 GABRG2 TRAF3 PIK3CA MYD88 CACNA1D TWNK COL3A1 PMS1 MTHFR CDKN2B KRIT1 HLA-DPB1 ND6 NLRP12 STAT4 MLX MSX2 PMS2 ADAMTSL1 PRRT2 SMAD3 SLC6A19 POLG DLST MEN1 DNMT3A THPO FASLG SOST AP2S1 OPA1 TRNQ SDHB TRNW CTLA4 NLRP3 SDHC EPAS1 GDF2 STOX1 SLC2A1 CFH PRKCD MSX2 COL5A1 CDH23 FGFR2 CD46 MLH1 KRAS IL23R COX2 PDGFRB TRNW CYB5R3 RNF168 COX3 NLRP3 SLC2A1 ACVRL1 AMACR ACVRL1 POLG ADA2 NDP RASA1 LPIN2 PDCD10 NF1 KYNU NF1 SLC12A3 SDHAF2 ESR1 FAS SLC25A4 ERF ATP1A2 AIP FAN1 PRTN3 TET2 NFIX SDHD PIGT TP53 GP1BB CLCNKB TRNS1 TLR4 TRNH CSNK1D COX1 F8 ATP1A2 TGFB1 ADRA2B C11ORF95 MVK TERT YEATS2 FLI1 CACNA1A TREX1 MEFV PIK3CA LRP5 PRRT2 GATA2 SEMA4A SDHA F8 VANGL1 IFIH1 DNM1L ZFHX2 EGF USP8 KIF1B NF2 PDGFB SOST FGFR2 FAS RET SAMHD1 ND1 MARCHF6 TREX1 SLC19A2 ND4 TNFRSF1A SUFU NF2 JAK2 CACNA1A TRNF CASP10 STAT4 CACNA1A POLG GPR101 IRAK1 BAP1 C4A GRIN2A CLCN2 TRNV SCN1A TMEM127 TRNQ APP TWNK MAX SLC1A3 PGK1 SMARCB1 SAMD12 CCR1 TRNS1 COX2 MDH2 UBAC2 ALX4 MSH6 PDCD10 AIP EPOR MEFV HTRA1 BMPR1A RNASEH2B FAS KCNA1 NOTCH3 STIM1 TNF TICAM1 CCM2 CYTB ND5 KL MSH2 ERAP1 CACNA1A SDHC FARSB AMER1 SPP1 TRNL1 TLR3 CDC73 ADA2 NOP56 JAK2 PTPN22 NOTCH2 AKT1 APP RELA VHL TRNF ADAR NLRP3 PGK1 KCNA1 MLH3 CNNM2 TBK1 ELANE CDC73 JAK2 COL4A1 ND5 SDHD SRPX2 PRRT2 FH KLRC4 TRAF7 PTPN22 ACP5 PTEN HLA-B FGFR3 RNASEH2A TRNS2 PRKAR1A CYP11B1 TWIST1 SCN1A SDHB CACNA1A MPL RASGRP1 VHL EPM2A MVK IL12A-AS1 HELLPAR ENG CDKN1B KIF23 GP9 EDNRA VHL CACNA1A CDKN1A BCAT2 SLC25A11 RET CTNND2 GP1BA COX3 COL5A2 IL12A KIT POLG2 SMAD4 IRF3 FGFR3 HLA-B
    Protein Mutations 0
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002315: Headache
    Genes 344
    NLRP3 ACSF3 SH2B1 CFI NAGS ND6 DKK1 TRNL1 RPS20 COL1A1 TRNK SOST TRNC SMO BRAF CDKN2C TWNK VHL CYP11B2 NHLRC1 CNNM2 APC RET APP KCNJ5 PEX11B CDH23 SH2B3 TRNS2 SPECC1L CTNNB1 CNTN2 SLC1A3 TNFRSF1A SLC2A1 MYORG TTR SPOP ND1 MPL KCNK18 CPT2 CDH23 PDGFB POLG IL12B HLA-DPA1 SLC2A1 EPCAM MSX2 IL10 ATP6 RRM2B SDHB DNAI1 TGFBR2 KCNA1 SDHD GBA CORIN ENG HTR1A MAOA RNASEH1 RNASEH2C NF1 LRP5 GCDH ADA2 RRM2B KRIT1 NOTCH3 TREX1 TWNK CCM2 SMARCB1 FLT1 SMARCE1 BAP1 MEN1 COX1 UNC93B1 GABRG2 TRAF3 PIK3CA MYD88 CACNA1D TWNK COL3A1 PMS1 MTHFR CDKN2B KRIT1 HLA-DPB1 ND6 NLRP12 STAT4 MLX MSX2 PMS2 ADAMTSL1 PRRT2 SMAD3 SLC6A19 POLG DLST MEN1 DNMT3A THPO FASLG SOST AP2S1 OPA1 TRNQ SDHB TRNW CTLA4 NLRP3 SDHC EPAS1 GDF2 STOX1 SLC2A1 CFH PRKCD MSX2 COL5A1 CDH23 FGFR2 CD46 MLH1 KRAS IL23R COX2 PDGFRB TRNW CYB5R3 RNF168 COX3 NLRP3 SLC2A1 ACVRL1 AMACR ACVRL1 POLG ADA2 NDP RASA1 LPIN2 PDCD10 NF1 KYNU NF1 SLC12A3 SDHAF2 ESR1 FAS SLC25A4 ERF ATP1A2 AIP FAN1 PRTN3 TET2 NFIX SDHD PIGT TP53 GP1BB CLCNKB TRNS1 TLR4 TRNH CSNK1D COX1 F8 ATP1A2 TGFB1 ADRA2B C11ORF95 MVK TERT YEATS2 FLI1 CACNA1A TREX1 MEFV PIK3CA LRP5 PRRT2 GATA2 SEMA4A SDHA F8 VANGL1 IFIH1 DNM1L ZFHX2 EGF USP8 KIF1B NF2 PDGFB SOST FGFR2 FAS RET SAMHD1 ND1 MARCHF6 TREX1 SLC19A2 ND4 TNFRSF1A SUFU NF2 JAK2 CACNA1A TRNF CASP10 STAT4 CACNA1A POLG GPR101 IRAK1 BAP1 C4A GRIN2A CLCN2 TRNV SCN1A TMEM127 TRNQ APP TWNK MAX SLC1A3 PGK1 SMARCB1 SAMD12 CCR1 TRNS1 COX2 MDH2 UBAC2 ALX4 MSH6 PDCD10 AIP EPOR MEFV HTRA1 BMPR1A RNASEH2B FAS KCNA1 NOTCH3 STIM1 TNF TICAM1 CCM2 CYTB ND5 KL MSH2 ERAP1 CACNA1A SDHC FARSB AMER1 SPP1 TRNL1 TLR3 CDC73 ADA2 NOP56 JAK2 PTPN22 NOTCH2 AKT1 APP RELA VHL TRNF ADAR NLRP3 PGK1 KCNA1 MLH3 CNNM2 TBK1 ELANE CDC73 JAK2 COL4A1 ND5 SDHD SRPX2 PRRT2 FH KLRC4 TRAF7 PTPN22 ACP5 PTEN HLA-B FGFR3 RNASEH2A TRNS2 PRKAR1A CYP11B1 TWIST1 SCN1A SDHB CACNA1A MPL RASGRP1 VHL EPM2A MVK IL12A-AS1 HELLPAR ENG CDKN1B KIF23 GP9 EDNRA VHL CACNA1A CDKN1A BCAT2 SLC25A11 RET CTNND2 GP1BA COX3 COL5A2 IL12A KIT POLG2 SMAD4 IRF3 FGFR3 HLA-B
    Protein Mutations 0
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook